NEW YORK (GenomeWeb) – Trovagene said today that it has entered into an agreement with Chinese genomics service provider Novogene under which Novogene will validate Trovagene's proprietary urine collection and nucleic acid preservation device, NextCollect, and develop tests for the Chinese market.

Trovagene is selling Novogene the NextCollect device along with reagents and methods to extract cell-free DNA (cfDNA) from urine. Novogene will then validate the platform at its own facilities, which include a CAP-accredited lab in Tianjin, China.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.